Technology evaluation: DISC

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 1, 1999, Pages 112-115

  Robertson, Erle S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE;

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMORAL IMMUNITY; LEUKEMIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; TREATMENT INDICATION; VACCINATION;

BIOTECHNOLOGY; CANCER VACCINES; CLINICAL TRIALS; CONDYLOMATA ACUMINATA; FEMALE; GENE THERAPY; HUMANS; NEOPLASMS; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

ANIMALIA; HERPES; HERPESVIRIDAE; MURINAE;

EID: 0032910938     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. 170245. Viagene Inc:Viagene Inc Common Stock. Company Communication (1993).
2. 176160. Target Genetics:Annual Report (1994).
3. 177132. Vical Inc:Merck exercises remaining naked DNA vaccine options. Press Release (1995).
4. 193984. McLean CS, Erturk M, Jennings R, Challanian DN, Minson AC, Duncan I, Boursnell ME, Inglis SC:Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis (1994) 170(5):1100-1109.
5. 227146. Cantab results for the third quarter ended September 38 1996 Cantab Pharmaceuticals, Press Release (1996) November 29.
6. 227199. Vical Inc:Vical Incorporated announces issuance of core technology patent. Press Release (1996).
7. 235908. Elliot G, O'Hare P:Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein. Cell (1997) 88 (24):223-233.
8. 239600. 1996 Preliminary Results and Corporate Strategy Cantab Pharmaceuticals plc, Press Release (1997) March 19.
9. 239647. Cantab Pharmaceuticals; Preliminary results meeting. IDdb meeting report, 19th March 1997, London.
10. 246977. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, Martin GM, Jennings R, Ni Challanaind, Sobek I, Inglis SC, McLean CS:A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis (1997) 175 (1):16-25.
11. 246988. McLean CS, Challanaind NI, Duncan I, Boursnell ME, Jennings R, Inglis SC:Induction of a protective Immune response by mucosal vaccination with a DISC-HSV-1 vaccine. Vaccine (1996) 14(10):987-992.
12. 249764. Temin HM:Overview of biological effects of addition of DNA molecules to cells. J Med Virol (1990) 31(1):13-17.
13. 249776. Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA:Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus [see comments]. Nat Med (1995) 1(6):583-587.
14. 249777. Shiver JW, Perry HC, Davles ME, Freed DC, Liu MA:Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. Ann NY Acad Sci (1995) 772:8.
15. 24977B. Nichols WW, Ledwith BJ, Manam SV, Troilo PJ:Potential DNA vaccine integration into host cell genome. Ann NY Acad Sci (1995) 772:30-39.
16. 2497B1. Montgomery DL, Donnelly JJ, Shiver JW, Liu MA, Ulmer JB:Protein expression in vivo by injection of polynucleotides. Curr Opin Biotechnol (1994) 5(5):505-510.
17. 249783. Montgomery DL, Shiver JW, Leander KR, Perry HC, Friedman A, Martinez D, Ulmer JB, Donnelly JJ, Liu MA:Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol (1993) 12(9):777-783.
18. 255708. Boursnell MEG, Entwisle C, Brenner M, Dilloo D, McLean CS, Blakeley DM, Shields JG, Inglis SC:Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer. Proc Am Assoc Cancer Res USA (1997) 38: Abs 2694.
19. 261004. Boursnell M, Entwisle C, Blakely D, Roberts C, Duncan I, Chisholm S, Martin G, Jennings R, Ni Challanain D, Sobek I, Inglis S, McLean C:A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis (1997) 175: 16-25.
20. 261148. Doe B, Selby M, Barnett S, Baenziger J, Walker C:Induction of Cytotoxic T-Lymphocytes by intramuscular immunization with plasmld DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci USA (1996) 93:8578-8583.
21. 268785. Loudon PT:In vivo evaluation of the risks of gene therapy products. Hum Exp Toxicol (1997) 16(7):393.
22. 268786. Hill S, Zhang X, Boursnell ME, Shields JG, Ricclardi Castagnolip, Hickling JK:Generation of a primary immune response to a genetically inactivated (DISC) herpes simplex virus and wild type virus. Biochem Soc Trans (1997) 25(2):200S.
23. 290637. Todryck S, McLean C, Boursnell M, Rees R, Vile R:A herpes simplex virus vector for gene therapy of colorectal cancer. Am Soc Gene Therapy (1998) 62a:245.